Full-Time
API Security Engineer
Updated on 9/16/2026
Moderna
5,001-10,000 employees
Develops mRNA-based medicines for health
Compensation Overview
$121.6k - $194.5k/yr
No H1B Sponsorship
Cambridge, MA, USA
Hybrid
Three days on-site and two days remote per week under the 70/30 working model.
 Cybersecurity (1) |
|---|
Get referred to Moderna
See people who can refer or advise you
- At least 5 years of experience in cybersecurity, application security, platform security, or a related engineering discipline, including meaningful hands-on API security experience.
- Strong understanding of API security risks and controls, including authentication, authorization, token handling, rate limiting, data exposure, input validation, and service-to-service trust models.
- Experience assessing or securing REST, GraphQL, or other modern API patterns in cloud-native or distributed application environments.
- Experience working with engineering and platform teams to improve API design, security posture, and operational controls.
- Familiarity with API gateways, service meshes, reverse proxies, or related control points used to secure and observe API traffic.
- Ability to perform threat modeling and technical risk assessments for APIs, integrations, backend services, and machine-to-machine interaction patterns.
- Working knowledge of identity and access concepts relevant to non-human identities, workload identities, and emerging agentic access patterns.
- Working knowledge of cloud and application security fundamentals, including identity, secrets management, logging, and common security design patterns.
- Strong analytical and troubleshooting skills, with the ability to turn technical findings into pragmatic remediation guidance.
- Strong written and verbal communication skills, with the ability to work across technical and non-technical stakeholder groups.
- Design, implement, and mature API security capabilities across enterprise applications, shared services, integrations, and AI-related platforms.
- Evaluate, deploy, and operationalize API security technologies for API discovery, posture assessment, traffic monitoring, anomaly detection, and policy enforcement.
- Partner with application, platform, and engineering teams to identify insecure API designs, weak authentication or authorization patterns, excessive data exposure, and other common API security risks.
- Perform API-focused threat modeling and security assessments for modern services, microservices, integrations, and AI-enabled workflows.
- Define and promote secure API engineering practices, including strong authentication, authorization, rate limiting, schema validation, secrets handling, and secure service-to-service communication.
- Shape security approaches for non-human and agentic identity models, including how services, automation, and software agents authenticate to APIs, obtain scoped access, and interact with sensitive systems safely.
- Analyze API telemetry and findings to identify abuse paths, misconfigurations, shadow APIs, and control gaps, then work with stakeholders to drive remediation.
- Collaborate with broader security teams to connect API security findings with cloud, application, identity, and detection engineering workflows.
- Provide practical engineering guidance to improve API security and address trust and identity challenges introduced by automation and AI-enabled systems.
- Familiarity with AI-enabled architectures or gateway patterns, particularly where APIs broker access to models, tools, or sensitive data flows.
Moderna develops medicines built on messenger RNA (mRNA). Its products use mRNA delivered into cells to instruct them to produce specific proteins that can prevent or treat disease, with vaccines being a primary example. In practice, a dose delivers engineered mRNA into the body, cells translate it into a target protein, and the immune system responds or the protein modulates biology to combat disease. Moderna differentiates itself through its focus on building a whole mRNA medicines platform and in-house capabilities for designing, manufacturing, and scaling mRNA therapies, including rapid development and large-scale production. Its goal is to create a new category of medicines based on mRNA that can improve how diseases are discovered, developed, and treated, ultimately improving patient outcomes.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2010
Get referred to Moderna
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 27, 2026 FDA approvals restored Spikevax and mNEXSPIKE for 2026-2027.
- Q2 2026 revenue rose to $145 million while cash costs fell 10%.
- Merck and Moderna plan melanoma approval filings within months after August 19.
What critics are saying
- February 2026 FDA refusal-to-file for mRNA-1010 left flu approval stalled in America.
- July 2025 layoffs cut 10% of staff, signaling a shrinking cost base and thinner execution.
- If Merck melanoma fails, Moderna becomes a one-product biotech by 2027.
What makes Moderna unique
- August 19, 2026, INTerpath-001 made Moderna and Merck first Phase 3 mRNA cancer-vaccine winners.
- Harwell's 2026 UK site gives Moderna integrated mRNA R&D and manufacturing capacity.
- Moderna still owns end-to-end mRNA design, clinical development, and commercialization.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
Sabbatical Leave
Hybrid Work Options
401(k) Company Match
Parental Leave
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Wellness Program
Mental Health Support
Phone/Internet Stipend
Home Office Stipend
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 1%DRC buries its dead twice: inside the Ebola outbreak, colliding with a war it cannot escape. The Bundibugyo strain tearing through eastern DRC has no vaccine, no approved treatment, and a body count outpacing every Ebola epidemic in history but one. It is spreading through provinces already emptied by militias, hunger and a peace deal that never quite held. OWN CORRESPONDENTS September 11, 2026 6 Mins Read IN the health zones around Mongbwalu and Bunia, in Ituri province, the arithmetic of this Ebola outbreak has become almost impossible to hold in the mind. A confirmed case is rarely just a patient. It is a household, a lineage of mourners who washed and touched a body before anyone knew what killed it, a clinic worker who has not left an isolation ward in weeks, a child now sleeping in a stranger's home because both parents are gone. Since the Democratic Republic of Congo's Ministry of Public Health declared its seventeenth Ebola outbreak on 15 May 2026, the virus has moved faster and killed more people in a shorter span than almost any Ebola epidemic ever recorded - and it is doing so inside one of the most violent, most neglected corners of the continent. By early September, the Congolese health ministry had confirmed 6,686 cases and 3,226 deaths, with more than 800 patients still fighting the virus in isolation wards. Only the West African epidemic of 2014 to 2016, which killed over 11,000 people across Guinea, Liberia and Sierra Leone, has claimed more lives. In terms of sheer velocity, this one has no precedent: roughly 5,000 cases accumulated in barely one hundred days, a pace the World Health Organisation's own director-general, Tedros Adhanom Ghebreyesus, has warned could eventually eclipse West Africa's death toll altogether. A VIRUS MEDICINE WAS NOT BUILT FOR Part of what makes this outbreak so lethal is the pathogen itself. Unlike the Zaire ebolavirus that drove the 2018-2020 Kivu outbreak and the West African epidemic before it, this one is caused by the Bundibugyo species - rarer, less studied, and historically just as deadly, with case fatality rates in past outbreaks ranging between 30 and 50 percent. Crucially, the monoclonal antibody treatments and the licensed rVSV-ZEBOV vaccine that transformed Ebola response over the past decade were built for the Zaire strain. Against Bundibugyo, they carry no regulatory approval and, according to the WHO's own technical advisers, insufficient evidence of protection. That has left responders relying on the oldest tools in outbreak medicine - supportive care, rehydration, isolation, contact tracing and safe burial - while a scramble for new countermeasures unfolds in real time. In late July, Oxford University enrolled its first volunteer in the world's first clinical trial of a vaccine candidate built specifically against Bundibugyo virus. Moderna has begun early trials of its own mRNA candidate. The WHO authorised a Phase 3 trial of the existing Ervebo vaccine in late July on the strength of animal data suggesting partial cross-protection, and by mid-August was negotiating with Congolese authorities to get a multi-arm vaccine trial running in the field within weeks. None of it changes the calculus for the thousands of families burying relatives this month: for this outbreak, there is still no shot to offer them. A WAR THAT WILL NOT PAUSE FOR A PLAGUE Ituri province, the outbreak's epicentre and home to 82 percent of all confirmed cases, is not merely under-resourced. It is contested territory. The Allied Democratic Forces, a Ugandan Islamist militia aligned with the Islamic State, has carried out repeated massacres in the province; more than 170 people were killed in armed-group violence in Ituri in May alone, the same month the outbreak was declared. CODECO factions, organised along ethnic lines, control swathes of rural territory outside state reach. To the south, in North and South Kivu, the Rwanda-backed M23 alliance holds Goma and large parts of the countryside, even as a Washington-brokered accord and a Doha peace framework technically bind Kinshasa and Kigali to a ceasefire. More than 2,100 people have been killed in that supposedly pacified east since the June 2025 agreement was signed. Over 120 armed groups now operate across the region. Response teams built their protocols for a health crisis. They are operating inside a war. Nearly one million people have been displaced from their homes in Ituri by conflict, scattering exactly the contact networks that epidemiologists need to trace. Doctors and nurses have fled overwhelmed, sometimes abandoned, health facilities. On 4 June, in Katana - a South Kivu town under the control of the Congo River Alliance/M23 - a burial team attempting to safely inter an Ebola victim was confronted by residents who seized the body and buried it themselves, exposing mourners to the very fluids the team had come to contain. Thirteen days later, in the Mongbwalu health zone, another burial team was attacked. On the same day as the Katana incident, eleven Ebola patients walked out of isolation facilities in Ituri, disappearing back into communities where health workers can no longer reliably follow them. The grief itself is part of the danger. In much of the Ituri and Kivu region, funerals can stretch across several days and involve washing, dressing and physically embracing the dead before burial - rites that carry deep spiritual weight and, with a haemorrhagic virus, lethal risk. Aid agencies describe communities caught between fear of the disease and fear of losing the right to mourn their own dead on their own terms, a tension that has repeatedly boiled over into violence against the very teams trying to protect them. THE CHILDREN LEFT BEHIND The epidemiology tells only part of the story. Save the Children has documented more than 300 child deaths in this outbreak by early August, and aid workers warn the deeper wound may be invisible on any case count: children who watch a parent die inside an isolation tent, then face suspicion and exclusion from the community that raised them. In the 2014-2016 West African epidemic, more than 30,000 children lost one or both parents to the virus. Humanitarian officials fear this outbreak, unfolding in a region where roughly 15 million people already needed humanitarian assistance before the first case was confirmed, could leave a comparable scar on a generation already living through displacement, hunger and war. Nearly ten million people across Ituri, North Kivu, South Kivu and Tanganyika are facing acute hunger, according to the latest food security assessments - part of a wider crisis in which roughly a quarter of the DRC's population, some 27 million people, now live with crisis-level food insecurity or worse. Ebola has not arrived in a vacuum. It has arrived on top of the hunger, on top of the guns, on top of a health system that was already, by aid agencies' own description, in a catastrophic state before the first patient in Bunia fell ill in early May. HOLDING THE LINE Despite the odds, the response has not collapsed. More than 1,700 Médecins Sans Frontières staff are working across five DRC provinces, running treatment centres from Mongbwalu to Komanda to Niania and reporting, as of 1 September, more than 1,400 survivors - proof that even against a strain with no vaccine, early supportive care saves lives. In Bunia, a local radio journalist has taken to the airwaves daily to fact-check rumours about the virus and connect frightened listeners to health specialists, a small but telling example of Congolese communities organising their own defence where international response plans fall short. The WHO has scaled up surveillance, cross-border preparedness with Uganda - which declared its own outbreak and briefly sealed its DRC border in late May - and community engagement teams working health zone by health zone. A TEST THE WORLD KEEPS FAILING TO LEARN FROM Every major Ebola epidemic of the past decade has taught the same lesson: the virus is rarely the hardest problem to solve. Distrust, conflict, poverty and the collapse of basic services are. The DRC's seventeenth outbreak is now the clearest test yet of whether that lesson has actually been absorbed - by Kinshasa, by the humanitarian system, and by a Rwanda-backed insurgency that shows little sign of loosening its grip on the very provinces where the outbreak burns hottest. For now, the count of the dead climbs faster than the count of the vaccinated, and in Ituri's health zones, communities continue doing what they have always done in the absence of anyone else able to help: burying their own, and hoping the next funeral is not their own.
Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.
Promising healthcare stocks to watch now - september 6th. Eli Lilly and Company, Moderna, and UnitedHealth Group are the three Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are shares of companies involved in the healthcare industry, including pharmaceuticals, biotechnology, medical devices, healthcare services, and health insurance. For investors, these stocks may offer growth opportunities driven by medical innovation and demographic trends, but they can also face risks from regulation, clinical-trial results, pricing pressures, and changing healthcare policies. These companies had the highest dollar trading volume of any Healthcare stocks within the last several days. Eli Lilly and Company (LLY). Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. Discover more Quarterly earnings forecast Business news summary Political news subscription Moderna (MRNA). Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. UnitedHealth Group (UNH). UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.
Moderna shares jumping 5.6% on S&P 500 biggest August 2026 winners: Moderna, software stocks. Moderna shares surged 5.6% on Tuesday, climbing to $148.22 as the biotechnology company emerged as one of the S&P 500's biggest winners for August 2026, wit... Economic news analysis Moderna shares surged 5.6% on Tuesday, climbing to $148.22 as the biotechnology company emerged as one of the S&P 500's biggest winners for August 2026, wit... AlphaStreet Newsdesk powered by AlphaStreet Intelligence
Moderna to present at upcoming conferences in September 2026. MWN-AI** Summary. Moderna, Inc. (Nasdaq: MRNA), a leader in mRNA technology, has announced its participation in two significant investor conferences in September 2026. The first event is the Morgan Stanley 24th Annual Global Healthcare Conference, scheduled for September 14 at 10:00 a.m. ET. Following that, Moderna will present at the Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum on September 23 at 8:50 a.m. ET. Investors and interested parties will have the opportunity to view live webcasts of both presentations, accessible through the "Events and Presentations" section on Moderna's investor website. These webcasts will also be archived for 30 days, allowing for broader access to Moderna's insights and updates. Moderna has positioned itself at the forefront of mRNA medicine, revolutionizing the healthcare landscape by transforming how diseases are treated and prevented. Since its inception, the company has leveraged its innovative mRNA platform to develop groundbreaking vaccines and therapies targeting various conditions, including infectious diseases, cancer, and rare disorders. The company's ongoing commitment to harnessing mRNA technology reflects its mission to create significant impacts on global health. With a global workforce dedicated to its core values and mission, Moderna aims to deliver transformative mRNA solutions that can address unmet medical needs. Investors seeking detailed company updates and information can reach out to Lavina Talukdar, Senior Vice President & Head of Investor Relations, for further inquiries. For those interested in learning more about Moderna's advancements and its vision for the future, the company encourages engagement through its website and various social media platforms. MWN-AI** Analysis. As Moderna, Inc. (NASDAQ: MRNA) prepares to present at two significant investor conferences in September 2026 - the Morgan Stanley 24th Annual Global Healthcare Conference and the Bernstein Insights: Healthcare Leaders and Disruptors Forum - investors should strategically assess the company's position and future potential in the biopharmaceutical market. Moderna has established itself as a leader in mRNA technology, an innovative platform that has transformed vaccine development and holds promise for various therapeutic applications. The upcoming conferences offer Moderna a platform to showcase new advancements, potentially announcing developments in its pipeline that could validate its growth trajectory and address ongoing industry challenges. Investors should watch for insights regarding Moderna's diversified pipeline, particularly in oncology and rare diseases, areas that may enhance its revenue streams beyond COVID-19 vaccines. Evaluating the company's research and development efforts, and potential collaborations or partnerships, can provide clues about its market competitiveness and innovation capabilities. Furthermore, given the current market dynamics and investor sentiment, Moderna's valuation could be influenced by external factors such as regulatory changes, competitive landscape shifts, and evolving public health needs. High volatility in biotech stocks necessitates cautious investment strategies, balancing the potential for high rewards against inherent risks. Key metrics to focus on include Moderna's financial health, clinical trial outcomes, market penetration for existing and new products, and overall alignment with global healthcare demands. Additionally, participating in the webcasts can provide real-time insights and allow investors to gauge leadership sentiment and strategic direction. In conclusion, it may be an opportune time for investors to consider their exposure to Moderna. Keeping a close eye on the outcomes of these conferences could yield actionable information to inform both short-term trading decisions and long-term investment strategies. **MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release. September 01, 2026 07:00:00 am CAMBRIDGE, MA / ACCESS Newswire / September 1, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: * Morgan Stanley 24th Annual Global Healthcare Conference, on Monday, September 14 at 10:00 a.m. ET * Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum, on Wednesday, September 23 at 8:50 a.m. ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation. About Moderna Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how Market Wire News treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with Market Wire News on X, Facebook, Instagram, YouTube and LinkedIn. Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations 617-209-5834 [email protected] FAQ**. What new developments can Market Wire News expect from Moderna Inc. (MRNA) in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026? I'm unable to predict specific developments from Moderna Inc. at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, as my knowledge is limited to data up to October 2023 and does not extend to future events or information. How will Moderna Inc. (MRNA) address the evolving healthcare landscape during the Bernstein Insights Forum on September 23, 2026? I'm unable to provide information on Moderna Inc.'s plans for the Bernstein Insights Forum on September 23, 2026, as my knowledge only extends until October 2023 and does not include future statements or developments. Can you elaborate on how Moderna Inc. (MRNA) plans to continue advancing its mRNA technology platform in 2026? Moderna Inc. plans to advance its mRNA technology platform in 2026 by focusing on broadening its vaccine pipeline, exploring therapeutic applications, and enhancing manufacturing capabilities to deliver more efficient and scalable solutions for various diseases. What key insights about mRNA medicine will Moderna Inc. (MRNA) share with investors during its upcoming presentations? Moderna Inc. is expected to share insights on the advancements in mRNA technology beyond COVID-19, focusing on new therapeutic applications, pipeline progress, and partnerships that enhance its development in areas like cancer treatments and rare diseases. **MWN-AI FAQ is based on asking OpenAI questions about Moderna Inc. (NASDAQ: MRNA).